These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Author: Valdivieso M, Bedikian AY, Burgess MA, Savaraj N, Jeffers WB, Bodey GP.
    Journal: Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017.
    Abstract:
    Dihydroxyanthracenedione is a new anthraquinone derivative with a wide spectrum of antitumor activity in experimental systems. A phase I clinical study was conducted using a 5-day iv schedule repeated every 3-4 weeks. Thirty-three adults with advanced refractory solid tumors received dihydroxyanthracenedione at daily doses ranging from 0.5 to 4 mg/m2. Neutropenia and, to a lesser degree, thrombocytopenia were dose-limiting toxic effects, although they were of brief duration. Other toxic effects were negligible. There were no complete or partial remissions in this study. We recommend that phase II studies of dihydroxyanthracenedione on a 5-day schedule use an initial daily dose of 4 mg/m2 for good-risk patients or 2-3 mg/m2 for poor-risk patients. Treatment courses can be repeated at 4-week intervals.
    [Abstract] [Full Text] [Related] [New Search]